Overall, these data indicated that the high expression of PARP10 was a feature of higher-risk AML, which is more frequently seen in older AML patients, TP53 mutant patients, and those with high-risk karyotypes, suggesting its clinical significance in predicting poorer clinical outcomes of AML patients. This evidence concerns the gene TP53 and acute myeloid leukemia.